Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …
Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
Once-weekly semaglutide in adults with overweight or obesity
JPH Wilding, RL Batterham, S Calanna… - … England Journal of …, 2021 - Mass Medical Soc
Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme
VR Aroda, R Bauer, E Christiansen… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aims To evaluate the efficacy and safety of oral semaglutide versus comparators by patient
characteristic subgroups in patients with type 2 diabetes. Materials and Methods Change …
characteristic subgroups in patients with type 2 diabetes. Materials and Methods Change …
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes
VR Aroda, U Erhan, P Jelnes, JJ Meier… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …
available as oral and subcutaneous formulations, and some have indications for reducing …
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
M Friedrichsen, A Breitschaft, S Tadayon… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To investigate the effects of once‐weekly subcutaneous (sc) semaglutide 2.4 mg on
gastric emptying, appetite, and energy intake in adults with obesity. Materials and Methods A …
gastric emptying, appetite, and energy intake in adults with obesity. Materials and Methods A …
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
B Ahrén, SL Atkin, G Charpentier… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims To assess the effect of baseline body mass index (BMI) and the occurrence of nausea
and/or vomiting on weight loss induced by semalgutide, a once‐weekly glucagon‐like …
and/or vomiting on weight loss induced by semalgutide, a once‐weekly glucagon‐like …
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
FK Knop, VR Aroda, RD do Vale, T Holst-Hansen… - The Lancet, 2023 - thelancet.com
Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including …
W Qin, J Yang, C Deng, Q Ruan… - Diabetes, Obesity and …, 2024 - Wiley Online Library
Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
L Jensen, V Kupcova, G Arold… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims To investigate whether the pharmacokinetic characteristics of semaglutide were
altered in people with hepatic impairment, assessed using Child–Pugh criteria, vs those with …
altered in people with hepatic impairment, assessed using Child–Pugh criteria, vs those with …
相关搜索
- semaglutide 2.4 gastrointestinal tolerability
- semaglutide 2.4 weight loss
- gastrointestinal tolerability weight loss
- adults with obesity effect of semaglutide
- tolerability of semaglutide trial programmes
- tolerability of semaglutide hepatic impairment
- adults with obesity control of eating
- adults with obesity energy intake
- adults with obesity gastric emptying
- baseline bmi weight loss
- receptor agonists weight loss